Atopic Dermatitis – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Atopic Dermatitis – Pipeline Review, H2 2019’, provides an overview of the Atopic Dermatitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Atopic Dermatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Atopic Dermatitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Atopic Dermatitis

– The report reviews pipeline therapeutics for Atopic Dermatitis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Atopic Dermatitis therapeutics and enlists all their major and minor projects

– The report assesses Atopic Dermatitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Atopic Dermatitis”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Atopic Dermatitis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Atopic Dermatitis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“Abate Med Inc

AbbVie Inc

Abeome Corp

Aclaris Therapeutics Inc

Afecta Pharmaceuticals Inc

Akaal Pharma Pty Ltd

Allergan Plc

Almirall SA

Amgen Inc

Amorepacific Corp

AOBiome LLC

Apimeds Inc

Arcutis Inc

Arena Pharmaceuticals Inc

Arrien Pharmaceuticals LLC

Asana BioSciences LLC

Aslan Pharmaceuticals Ltd

Astellas Pharma Inc

AstraZeneca Plc

Atrapos Therapeutics LLC

Azitra Inc

Bausch Health Companies Inc

Biomimetix JV LLC

Blueberry Therapeutics Ltd

Boehringer Ingelheim International GmbH

Boston Pharmaceuticals Inc

Botanix Pharmaceuticals Ltd

Calcico Therapeutics Ltd

Celgene Corp

ChironWells GmbH

Chugai Pharmaceutical Co Ltd

Clayton Biotechnologies Inc

Clevexel Pharma SAS

CSA Biotechnologies LLC

Cutanea Life Sciences Inc

Daiichi Sankyo Co Ltd

Dermata Therapeutics LLC

Dermavant Sciences Inc

DermBiont Inc

Devonian Health Group Inc

DongKoo Bio & Pharma Co Ltd

DURECT Corp

EHL Bio Co Ltd

Eli Lilly and Co

Evelo Biosciences Inc

Evotec SE

F. Hoffmann-La Roche Ltd

Fountain Biopharma Inc

Galapagos NV

Galderma SA

General Regeneratives Shanghai Ltd

GI Innovation Co Ltd

GlaxoSmithKline Plc

Helix BioMedix Inc

Hill Dermaceuticals Inc

Hoth Therapeutics Inc

Huons Co Ltd

Ichnos Sciences Inc

Immune Pharmaceuticals Inc

Incyte Corp

Inflamalps SA

Innovation Pharmaceuticals Inc

Innovimmune Biotherapeutics Inc

Japan Tobacco Inc

Jiangsu Hengrui Medicine Co Ltd

JiangSu Qyuns Therapeutics Co Ltd

JW Pharmaceutical Corp

Kang Stem Biotech Co Ltd

Kine Sciences

Kiniksa Pharmaceuticals Corp

KoBioLabs Inc

Krystal Biotech Inc

Kv1.3 Therapeutics

Kymab Ltd

Kyowa Kirin Co Ltd

Larix Bioscience LLC

Lead Pharma Holding BV

Lemonex Inc

Leo Pharma AS

Lipid Biologics LLC

Lypanosys Pte Ltd

Madam Therapeutics BV

Matrisys Bioscience Inc

MC2 Therapeutics AS

Medicenna Therapeutics Corp

Micreos BV

Nektar Therapeutics

Nepsone ehf

Neuracle Science Co Ltd

NeuroCycle Therapeutics GmbH

Next Science Ltd

NovaCell Technology Inc

Novan Inc

Novartis AG

Oasis Pharmaceuticals LLC

OliX Pharmaceuticals Inc

Ondek Pty Ltd

Orbis Biosciences Inc

Otsuka Holdings Co Ltd

Pantherics Inc

Pfizer Inc

PHI Therapeutics Inc

Polyrizon Ltd

Portola Pharmaceuticals Inc

Provectus Biopharmaceuticals Inc

Pyramid Biosciences Inc

Qurient Co Ltd

Ralexar Therapeutics Inc

RAPT Therapeutics Inc

Regeneron Pharmaceuticals Inc

Ribomic Inc

SCM lifescience Co Ltd

Seelos Therapeutics Inc

Servatus Ltd

Shaperon Inc

Shulov Innovative Science Ltd

Sienna Biopharmaceuticals Inc

Signum Biosciences Inc

Signum Dermalogix Inc

Sosei Heptares

Spherium Biomed SL

StemRIM Inc

sterna biologicals Gmbh & Co KG

Suzhou Connect Biopharmaceuticals Ltd

Suzhou Zelgen Biopharmaceutical Co Ltd

TaiwanJ Pharmaceuticals Co Ltd

Temisis Therapeutics

The Geneva Biotech Center SA

Therabest Co Ltd

Tianjin Hemay Bio-Tech Co Ltd

Tolerys SA

Torrent Pharmaceuticals Ltd

Transdermal Therapeutic Technologies LLC

Union Therapeutics AS

Vasomune Inc

VivaCell Biotechnology Espana SL

Voronoi

vTv Therapeutics Inc

Welichem Biotech Inc

XBiotech Inc

Xencor Inc

Zhejiang I-Biological Technology Co Ltd”

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Atopic Dermatitis (Atopic Eczema) Overview 7

Atopic Dermatitis (Atopic Eczema) Therapeutics Development 8

Atopic Dermatitis (Atopic Eczema) Therapeutics Assessment 26

Atopic Dermatitis (Atopic Eczema) Companies Involved in Therapeutics Development 38

Atopic Dermatitis (Atopic Eczema) Drug Profiles 73

Atopic Dermatitis (Atopic Eczema) Dormant Projects 404

Atopic Dermatitis (Atopic Eczema) Discontinued Products 412

Atopic Dermatitis (Atopic Eczema) Product Development Milestones 414

Appendix 425

List of Tables

“List of Tables

Table 1: Number of Products under Development for Atopic Dermatitis (Atopic Eczema), H2 2019

Table 2: Number of Products under Development by Companies, H2 2019

Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Table 4: Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Table 5: Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Table 6: Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Table 7: Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019

Table 8: Number of Products under Development by Companies, H2 2019 (Contd..6), H2 2019

Table 9: Number of Products under Development by Companies, H2 2019 (Contd..7), H2 2019

Table 10: Number of Products under Development by Universities/Institutes, H2 2019

Table 11: Products under Development by Companies, H2 2019

Table 12: Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Table 13: Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Table 14: Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Table 15: Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Table 16: Products under Development by Companies, H2 2019 (Contd..5), H2 2019

Table 17: Products under Development by Companies, H2 2019 (Contd..6), H2 2019

Table 18: Products under Development by Companies, H2 2019 (Contd..7), H2 2019

Table 19: Products under Development by Companies, H2 2019 (Contd..8), H2 2019

Table 20: Products under Development by Companies, H2 2019 (Contd..9), H2 2019

Table 21: Products under Development by Companies, H2 2019 (Contd..10), H2 2019

Table 22: Products under Development by Universities/Institutes, H2 2019

Table 23: Number of Products by Stage and Target, H2 2019

Table 24: Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019

Table 25: Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019

Table 26: Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019

Table 27: Number of Products by Stage and Mechanism of Action, H2 2019

Table 28: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019

Table 29: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019

Table 30: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019

Table 31: Number of Products by Stage and Route of Administration, H2 2019

Table 32: Number of Products by Stage and Molecule Type, H2 2019

Table 33: Atopic Dermatitis (Atopic Eczema) – Pipeline by Abate Med Inc, H2 2019

Table 34: Atopic Dermatitis (Atopic Eczema) – Pipeline by AbbVie Inc, H2 2019

Table 35: Atopic Dermatitis (Atopic Eczema) – Pipeline by Abeome Corp, H2 2019

Table 36: Atopic Dermatitis (Atopic Eczema) – Pipeline by Aclaris Therapeutics Inc, H2 2019

Table 37: Atopic Dermatitis (Atopic Eczema) – Pipeline by Afecta Pharmaceuticals Inc, H2 2019

Table 38: Atopic Dermatitis (Atopic Eczema) – Pipeline by Akaal Pharma Pty Ltd, H2 2019

Table 39: Atopic Dermatitis (Atopic Eczema) – Pipeline by Allergan Plc, H2 2019

Table 40: Atopic Dermatitis (Atopic Eczema) – Pipeline by Almirall SA, H2 2019

Table 41: Atopic Dermatitis (Atopic Eczema) – Pipeline by Amgen Inc, H2 2019

Table 42: Atopic Dermatitis (Atopic Eczema) – Pipeline by Amorepacific Corp, H2 2019

Table 43: Atopic Dermatitis (Atopic Eczema) – Pipeline by AOBiome LLC, H2 2019

Table 44: Atopic Dermatitis (Atopic Eczema) – Pipeline by Apimeds Inc, H2 2019

Table 45: Atopic Dermatitis (Atopic Eczema) – Pipeline by Arcutis Inc, H2 2019

Table 46: Atopic Dermatitis (Atopic Eczema) – Pipeline by Arena Pharmaceuticals Inc, H2 2019

Table 47: Atopic Dermatitis (Atopic Eczema) – Pipeline by Arrien Pharmaceuticals LLC, H2 2019

Table 48: Atopic Dermatitis (Atopic Eczema) – Pipeline by Asana BioSciences LLC, H2 2019

Table 49: Atopic Dermatitis (Atopic Eczema) – Pipeline by Aslan Pharmaceuticals Ltd, H2 2019

Table 50: Atopic Dermatitis (Atopic Eczema) – Pipeline by Astellas Pharma Inc, H2 2019

Table 51: Atopic Dermatitis (Atopic Eczema) – Pipeline by AstraZeneca Plc, H2 2019

Table 52: Atopic Dermatitis (Atopic Eczema) – Pipeline by Atrapos Therapeutics LLC, H2 2019

Table 53: Atopic Dermatitis (Atopic Eczema) – Pipeline by Azitra Inc, H2 2019

Table 54: Atopic Dermatitis (Atopic Eczema) – Pipeline by Bausch Health Companies Inc, H2 2019

Table 55: Atopic Dermatitis (Atopic Eczema) – Pipeline by Biomimetix JV LLC, H2 2019

Table 56: Atopic Dermatitis (Atopic Eczema) – Pipeline by Blueberry Therapeutics Ltd, H2 2019

Table 57: Atopic Dermatitis (Atopic Eczema) – Pipeline by Boehringer Ingelheim International GmbH, H2 2019

Table 58: Atopic Dermatitis (Atopic Eczema) – Pipeline by Boston Pharmaceuticals Inc, H2 2019

Table 59: Atopic Dermatitis (Atopic Eczema) – Pipeline by Botanix Pharmaceuticals Ltd, H2 2019

Table 60: Atopic Dermatitis (Atopic Eczema) – Pipeline by Calcico Therapeutics Ltd, H2 2019”

List of Figures

“List of Figures

Figure 1: Number of Products under Development for Atopic Dermatitis (Atopic Eczema), H2 2019

Figure 2: Number of Products under Development by Companies, H2 2019

Figure 3: Number of Products under Development by Universities/Institutes, H2 2019

Figure 4: Number of Products by Top 10 Targets, H2 2019

Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019

Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019

Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Figure 8: Number of Products by Top 10 Routes of Administration, H2 2019

Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Figure 10: Number of Products by Top 10 Molecule Types, H2 2019

Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports